Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

This study has been completed.

Study NCT00049569 Information provided by National Cancer Institute (NCI)

First Received: November 12, 2002 Last Updated: December 17, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Publications:

Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol. 2008 Aug 20;26(24):3971-8.

Raetz EA, Borowitz MJ, Devidas M, et al.: Outcomes of children with first marrow relapse: results from Childrens Oncology Group (COG) study AALL01P2. [Abstract] Blood 108 (11): A-1871, 2006.

Borowitz MJ, Devidas M, Hunger SP, et al.: Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) in relapse. A Children's Oncology Group (COG) study. [Abstract] Blood 104 (11): A-324, 2004.